From the Department of Anesthesiology and Perioperative Medicine, Queen's University, Kingston, Ontario, Canada.
Department of Clinical Pharmacology, Université Clermont Auvergne, Clermont-Ferrand, France.
Anesth Analg. 2020 Sep;131(3):764-775. doi: 10.1213/ANE.0000000000004673.
Chronic pain is a highly prevalent and complex health problem that is associated with a heavy symptom burden, substantial economic and social impact, and also, very few highly effective treatments. This review examines evidence for the efficacy and safety of magnesium in chronic pain. The previously published protocol for this review was registered in International Prospective Register of Systematic Reviews (PROSPERO), MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched until September 2018. We included randomized controlled trials (RCTs) comparing magnesium (at any dose, frequency, or route of administration) with placebo using participant-reported pain measures. A total of 9 RCTs containing 418 participants were included. Three studies examined neuropathic pain (62 participants), 3 examined migraines (190 participants), 2 examined complex regional pain syndrome (86 participants), and 1 examined low back pain with a neuropathic component (80 participants). Heterogeneity of included studies precluded any meta-analyses. No judgment could be made about safety because adverse events were inconsistently reported in the included studies. Evidence of analgesic efficacy from included studies was equivocal. However, reported efficacy signals in some of the included trials provide a rationale for more definitive studies. Future, larger-sized trials with good assay sensitivity and better safety assessment and reporting, as well as careful attention to formulations with optimal bioavailability, will serve to better define the role of magnesium in the management of chronic pain.
慢性疼痛是一种普遍且复杂的健康问题,其症状负担重,对经济和社会有重大影响,且有效的治疗方法非常有限。本综述考察了镁治疗慢性疼痛的疗效和安全性证据。本综述的先前发表方案已在国际前瞻性系统评价注册库(PROSPERO)、MEDLINE、EMBASE 和 Cochrane 对照试验中心注册库(CENTRAL)中进行了检索,检索时间截至 2018 年 9 月。我们纳入了比较镁(任何剂量、频率或给药途径)与安慰剂的随机对照试验(RCT),采用参与者报告的疼痛测量指标。共纳入了 9 项包含 418 名参与者的 RCT。3 项研究检查了神经性疼痛(62 名参与者),3 项研究检查了偏头痛(190 名参与者),2 项研究检查了复杂性区域疼痛综合征(86 名参与者),1 项研究检查了伴有神经性成分的腰痛(80 名参与者)。由于纳入研究存在异质性,因此无法进行任何荟萃分析。由于纳入研究中不良反应报告不一致,因此无法对安全性做出判断。纳入研究的镇痛疗效证据存在争议。然而,一些纳入试验中报告的疗效信号为更明确的研究提供了依据。未来,需要更大规模、具有良好检测灵敏度、更好的安全性评估和报告,以及仔细关注具有最佳生物利用度的配方的试验,将有助于更好地确定镁在慢性疼痛管理中的作用。